Cesca Therapeutics - רווח נקי למניה ב-12 החודשים האחרונים THMO

ThermoGenesis generates revenue by supplying cell freezing and processing systems to biobanks. High B2B customer loyalty is secured through proprietary cartridges and strict FDA oversight. The PXP technology stack, featuring AI analysis, creates a closed-loop research cycle. Historical EPS YoY TTM dynamics demonstrate the resilience of fundamental indicators, with the metric remaining around 67.70.

The monetization potential of ThermoGenesis (THMO) software determines the long-term value of the business. The trend in the annual percentage change of EPS TTM captures the difference in net income per share over the last 12 months relative to the previous year, excluding seasonal distortions. Current fluctuations on the chart reflect management's struggle with a liquidity shortage. High peaks of the indicator here signal a risk of overpayment. Investment attractiveness remains uncertain until cash flows stabilize.